Dr. Shahidi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 E Carpenter St
Springfield, IL 62769Phone+1 217-528-7541
Education & Training
Southern Illinois UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2012 - 2014- Southern Illinois UniversityResidency, Internal Medicine, 2009 - 2012
Istanbul University FomClass of 2006
Certifications & Licensure
IL State Medical License 2011 - 2026
MO State Medical License 2017 - 2026
CA State Medical License 2013 - 2023
NY State Medical License 2016 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 2474 citationsPhase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Vera Hirsh
Journal of Clinical Oncology. 2013-09-20 - 237 citationsSymptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR MutationsJames Chih-Hsin Yang, Vera Hirsh, Martin Schuler, Nobuyuki Yamamoto, Kenneth J. O'Byrne
Journal of Clinical Oncology. 2013-09-20 - 271 citationsLUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or BothNobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai
Journal of Clinical Oncology. 2013-09-20
Press Mentions
New Data Showed OFEV® (Nintedanib) Slows Decline of Lung Function in Broad Range of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype(1)November 27th, 2019
Ofev Reduces Lung Function Decline in Patients with Fibrotic Lung Diseases, Phase 3 Trial ShowsOctober 2nd, 2019
INBUILD® Meets Primary Endpoint - Study Evaluated Nintedanib in Patients Across a Range of Progressive Fibrosing Interstitial Lung diseases1September 30th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
